SCHEDULE: Novo Holdings Discloses 8.8% Stake in Avalyn Pharma

Novo Holdings A/S has reported beneficial ownership of 3,883,289 shares, representing 8.8% of Avalyn Pharma Inc.'s common stock.

Summary

• Novo Holdings A/S, a Danish investment firm, has filed a Schedule 13G indicating beneficial ownership of 3,883,289 shares of Avalyn Pharma Inc. common stock.
• This holding represents 8.8% of the total class of securities.
• Novo Holdings A/S is wholly owned by the Novo Nordisk Foundation, but the Foundation itself is not deemed to have beneficial ownership of these securities.
• The filing is dated June 30, 2026, with the report submitted on August 14, 2026.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive filing, primarily indicating a significant investment stake rather than new strategic developments or performance updates.

Positives

• Significant investment by a reputable life sciences investor (Novo Holdings A/S) suggests confidence in Avalyn Pharma's potential.
• The 8.8% stake indicates a substantial commitment to the company's future.

Negatives

• The filing does not provide any financial performance data or operational updates for Avalyn Pharma Inc.

Risks

• As a Schedule 13G filing, it primarily reports ownership and does not detail specific risks associated with Avalyn Pharma's operations or market position.
• The concentration of ownership by a single entity could influence corporate governance decisions.

Future Outlook

This filing does not contain forward-looking statements or guidance regarding Avalyn Pharma Inc.'s future performance.

Management Comments

• Novo Holdings A/S is an investment firm focused on life sciences and finance that is wholly owned by Novo Nordisk Foundation.
• Novo Holdings A/S is responsible for managing the Foundation's assets, including its financial assets.
• Based on the governance structure of Novo Holdings A/S and the Foundation, the Foundation is not deemed to have any beneficial ownership of the securities of the Issuer held by Novo Holdings A/S.

Industry Context

StockSavvy.ai notes that significant stakes taken by specialized investment firms like Novo Holdings A/S in biotechnology or pharmaceutical companies are common, often signaling a belief in the company's research and development pipeline or market potential.

Stakeholder Impact

• Shareholders: May view the investment by Novo Holdings A/S positively, potentially increasing investor confidence and share value.
• Management: May face increased scrutiny or influence from a large, strategic shareholder.
• Creditors: No immediate impact indicated, but long-term strategic shifts could affect financial stability.

Next Steps

• Monitor Avalyn Pharma Inc. for future operational and financial disclosures.
• Observe potential strategic actions or influence from Novo Holdings A/S as a significant shareholder.

Key Dates

Keywords

Novo Holdings A/S, Avalyn Pharma Inc., Schedule 13G, Beneficial Ownership, Investment, Common Stock, Life Sciences